Publication | Closed Access

Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study

Diabetes ManagementMedicineDiabetesDiabetic NeuropathyPharmacotherapyNeurologyClinical BenefitDiabetes MellitusAldose Reductase InhibitorPharmacology